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Serotonin syndrome is an acute condition resulting from
serotonin over-activity in the central nervous system,
characterized by a triad of mental, autonomic and
neurological symptoms.1 The symptoms can be distressing
to the point of becoming unbearable for the sufferer,
making prompt diagnosis essential. Alhough a potentially
fatal condition, most cases of serotonin syndrome have a
good prognosis if the cause is effectively addressed (i.e.,
removal of the offending agents).2
CASE REPORT
A 40-year-old married lady presented to the psychiatry
outpatient clinic for a second opinion. She had a 15-year
history of recurrent depression and had taken an overdose
with serious intent one week prior to admission.  
Her recent episode of depression was not improving
despite trials with different antidepressants in sufficient
doses and duration. Her medications included venlafaxine
150mg/day and paroxetine 20 mg/day. Three days after
initiation of these medications she began experiencing
increased anxiety symptoms, remained very agitated and
was unable to concentrate. Jerky movements were noted
in the upper limbs, accompanied by a twitching sensation
in the body, epigastric discomfort, and bloating of the
abdomen. As her symptoms persisted without relief, she
decided to take an excess dose of her prescribed
medications. A nearby hospital performed gastric lavage
but the symptoms persisted.
At the time of presentation to our facility, her pulse was
105/min,  b lood pressure  140/95 mm Hg,  and
respiratory rate 30/min. She was afebrile and had warm,
sweaty palms. Tendon reflexes were exaggerated with
bilateral myoclonus in the upper limbs. She was unable
to walk due to dizziness. Her abdomen was tender in the
epigastrium on deep palpation. Routine laboratory
investigations from one week earlier were within normal
limits. She was admitted to the psychiatry ward with a
diagnosis of serotonin syndrome.    
During her admission, venlafaxine and paroxetine were
discontinued and supportive therapy was initiated with
full recovery. On an outpatient follow-up visit one week
later, her symptoms had completely resolved. After an
interval of three weeks, fluoxetine was started, and her
depressive symptoms showed improvement. Thereafter,
the patient was lost to follow-up.
D I S C U S S I O N
Serotonin synd rome is  an important  bu t under -
recognized complication of serotonin-specific re-uptake
inhibitors (SSRIs). The onset could be within hours.
Almost three quarters of patients present within 24
hours of initiation or change in dose of serotonergic
m e d i c a t i o n s .6 However, our patient developed symptoms
after 3 days. Left untreated, mortality can approach 11-
1 5 % .
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ABSTRACT
Serotonin syndrome is a potentially fatal complication of psychotropic medication that  enhance serotonin
neurotransmission. The risk of self-harm may increase due to the distressing symptoms of this syndrome. We report the
case of a 40-year-old woman who took an overdose of a combination of two serotonin re-uptake inhibitors, venlafaxine and
paroxetine.
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Serotonin syndrome occurs as a result of over-stimulation
of 5-HT1A receptors in central grey nuclei and the
medulla.2,3,5,6 The most common presenting features are
confusion, agitation, tachycardia and myoclonus.7 There is
no specific confirmatory test; the diagnosis is based on
clinical assessment and judgment. Our patient did fulfill a
set of formal clinical criteria, the Radomski diagnostic
criteria, for serotonin syndrome.8
Combined use of two serotonergic medications is more
likely to cause serotonin syndrome, as was the case in our
patient. It is important to consider serotonin syndrome in
the differential diagnosis of similar symptoms that may
caused by psychotropic medication, such as neuroleptic
malignant syndrome and overdose of certain psycho-
stimulants such as the recreational drug Ecstasy. 
The need to be aware of this fatal complication has
important implications. Clinicians must recognize that
complaints of agitation and restlessness may be iatrogenic
and not part of the presenting il lness. Appropriate
management can reduce the rising risk of self-harm, as
happened with our patient. Although it is believed that
overdoses of SSRIs are relatively safe compared with
overdoses of tricyclic anti-depressants, in vulnerable
individuals overdoses of SSRIs may be fatal.
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